Agents in development for the treatment of diabetic nephropathy

Su Yen Goh, Mariusz Jasik, Mark E. Cooper

Research output: Contribution to journalReview ArticleResearchpeer-review

16 Citations (Scopus)


Background: Nephropathy is a major cause of morbidity and mortality in diabetic patients. Current treatments include optimization of glycemic and blood pressure control, but more innovative strategies are needed for the prevention and treatment of diabetic nephropathy. Objectives: To review emerging therapies for diabetic nephropathy. Methods: This paper discusses the molecular mechanisms of diabetic nephropathy and the potential therapeutic interventions. Results/conclusion: New therapies, including those targeting the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS) generation, are likely to feature in future treatment regimens. Other approaches that at this stage do not appear to be progressing include the glycosaminoglycan sulodexide and the protein kinase C-beta (PKC-β) inhibitor, ruboxistaurin.

Original languageEnglish
Pages (from-to)447-463
Number of pages17
JournalExpert Opinion on Emerging Drugs
Issue number3
Publication statusPublished - 1 Sept 2008
Externally publishedYes


  • Advanced glycation
  • Complications
  • Diabetes mellitus
  • Diabetic nephropathy
  • Glycosaminoglycans
  • Growth-factors
  • Protein kinase C inhibition
  • Renin-angiotensin-aldosterone system

Cite this